The Mumbai-based pharmaceutical firm benefits from a 180-day period of generic drug exclusivity for the product. This launch targets a significant segment of the cardiovascular sector, with the reference drug recording estimated annual sales of $53.5 million in the United States as of April 2026, according to IQVIA data. By expanding its portfolio with this complex generic, the company aims to strengthen its footprint in the American market, where it already maintains a presence across multiple therapeutic areas including respiratory, anti-diabetic, and gastrointestinal health.